List view / Grid view
While the introduction of novel immunotherapies to combat and treat cancer has advanced patient care greatly, ever more effective solutions continue to be required. Here, Dr Edmond Chan, Senior Director, EMEA Therapeutic Area Lead, Haemato-Oncology at Janssen Europe, Middle East & Africa (EMEA), explores how T-cell redirecting bispecific antibodies (TRBAs)…
Scientists from Stanford University have been able to halt the growth of multiple myeloma and diffuse large B cell lymphoma in mice with custom molecule sBCMA-Fc V3.
A new CAR T-cell therapy for B-cell cancers promises to reduce the antigen escape currently found in therapies that only target CD19.
During investigations into the tropical disease Buruli ulcer, researchers have instead identified a promising new avenue for potential treatments for multiple myeloma.
Having identified the histone demethylase KDM5A as a multiple myeloma target, researchers developed a KDM5 inhibitor to treat the cancer.
Researchers have discovered that two enzymes called APOBEC3C and ADAR1 work together to fuel the transition from pre-cancer stem cells to cancer stem cells in leukaemia.
An antisense oligonucleotide has been developed by researchers to inhibit IRF4 as a potential strategy to treat multiple myeloma.
An α-radioimmunotherapy called 212Pb-anti-CD38 was effective at preventing tumour growth and increasing survival in multiple myeloma tumour-bearing mice, a study has shown.
A new compound, called FL118, was effective at combatting multiple myeloma in advanced stages of the condition in patient samples as well as mice, say researchers.
Researchers have created a CAR T-cell therapy which targets the CD229 molecule expressed on all multiple myeloma cells and killed human tumour cells in mice.
It may be better to examine the urine and the blood of patients suspected of tumours of the plasma cells...
Researchers uncovered a new way to enhance the function of a specific type of immune cell that destroys tumours in multiple myeloma...
1 September 2016 | By Niamh Louise Marriott, Digital Content Producer
Takeda’s global non-interventional, observational multiple myeloma study is now enrolling patients, aiming to have 5,000 patients over three years with a goal of following each patient for a minimum of five years in an effort to track patterns in disease presentation, patient characteristics, treatment and outcomes, thereby enhancing the understanding…
